• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Pacira’s (PCRX) U.S. Manufacturing Shift for PCRX-201 Redefine Its Post-EXPAREL Narrative?

    Simply Wall St·08/01/2026 22:31:04
    Listen to the news
    • Pacira BioSciences recently transitioned its investigational knee osteoarthritis gene therapy PCRX-201 to a scalable U.S.-based commercial manufacturing process and began enrolling patients into Part B of its Phase 2 ASCEND trial, while keeping the program on schedule.
    • This progress not only advances one of Pacira’s highest-profile pipeline assets, supported by RMAT and ATMP designations, but also showcases the broader commercial potential of its high-capacity adenovirus gene therapy platform across common musculoskeletal diseases.
    • Next, we’ll examine how this successful U.S. manufacturing transition for PCRX-201 could influence Pacira’s investment narrative around diversification beyond EXPAREL.

    AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    Pacira BioSciences Investment Narrative Recap

    To own Pacira, you need to believe EXPAREL can keep funding a broader non opioid and regenerative portfolio while newer assets like PCRX-201 gradually matter more. The clean U.S. manufacturing transition and on time ASCEND Part B enrollment are positives for diversification, but near term, EXPAREL access, pricing, and upcoming earnings remain the key catalyst, while reliance on one product is still the central risk.

    Among recent updates, UnitedHealthcare’s move to reimburse EXPAREL separately for about 40 million covered lives stands out alongside the PCRX-201 news. Together, improved EXPAREL access and a de risked manufacturing path for PCRX-201 frame Pacira’s catalysts around both strengthening the core franchise and building a second leg of growth, even as investors weigh reimbursement pressure and clinical trial execution risk.

    Yet, against this encouraging PCRX-201 progress, investors should also weigh the risk that intensifying cost controls and payer scrutiny could still limit how much value Pacira ultimately captures from...

    Read the full narrative on Pacira BioSciences (it's free!)

    Pacira BioSciences’ narrative projects $908.9 million revenue and $112.0 million earnings by 2028.

    Uncover how Pacira BioSciences' forecasts yield a $29.00 fair value, a 10% upside to its current price.

    Exploring Other Perspectives

    PCRX 1-Year Stock Price Chart
    PCRX 1-Year Stock Price Chart

    Some of the lowest ranked analysts paint a much tougher picture than the consensus, assuming only about US$865,000,000 of revenue and US$97,100,000 of earnings by 2029, so this new PCRX-201 progress could either soften that cautious view or reinforce concerns about whether cost pressure and reimbursement hurdles will blunt the benefits of pipeline wins.

    Explore 3 other fair value estimates on Pacira BioSciences - why the stock might be worth just $29.00!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.